Sivia Capital Partners LLC Grows Holdings in Novo Nordisk A/S (NYSE:NVO)

Sivia Capital Partners LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 9.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,733 shares of the company’s stock after buying an additional 784 shares during the quarter. Sivia Capital Partners LLC’s holdings in Novo Nordisk A/S were worth $606,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in NVO. GQG Partners LLC boosted its position in Novo Nordisk A/S by 74.7% during the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock valued at $1,117,790,000 after purchasing an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $404,910,000. Loomis Sayles & Co. L P raised its stake in shares of Novo Nordisk A/S by 34.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock worth $995,397,000 after purchasing an additional 2,947,771 shares during the last quarter. Nuveen Asset Management LLC raised its stake in shares of Novo Nordisk A/S by 73.2% in the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company’s stock worth $537,189,000 after purchasing an additional 2,639,693 shares during the last quarter. Finally, Two Sigma Investments LP purchased a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $158,657,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $74.70 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The firm has a market capitalization of $335.22 billion, a PE ratio of 22.71, a P/E/G ratio of 0.90 and a beta of 0.66. The business’s 50 day moving average price is $65.87 and its 200-day moving average price is $80.54.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The firm had revenue of $11.87 billion during the quarter. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on NVO shares. Hsbc Global Res upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, April 28th. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Stifel Nicolaus lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Friday. Finally, Guggenheim lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $128.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.